Brunei Darussalam

Population 2018: <1 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>0.29 (0.25–0.33)</td>
<td>88 (58–78)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>&lt;0.01 (0–&lt;0.01)</td>
<td>0.8 (0.1–2.2)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>0 (0–0)</td>
<td>0 (0–0)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>0.016 (0.015–0.016)</td>
<td>36 (3.6–3.7)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0 (0–&lt;0.01)</td>
<td>0.12 (0.01–0.35)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018
- New cases: 0% (0–1.9)
- Previously treated cases: 0% (0–60)

TB case notifications, 2018
- Total new and relapse: 252
  - % tested with rapid diagnostics at time of diagnosis: 100%
  - % with known HIV status: 100%
  - % pulmonary: 81%
  - % bacteriologically confirmed***: 98%
  - % children aged 0-14 years: 2%
  - % women: 41%
  - % men: 57%
- HIV-negative TB mortality: 0.016 (0.015–0.016)
- HIV-positive TB mortality: 0.12 (0.01–0.35)

Universal health coverage and social protection
- TB treatment coverage (notified/estimated incidence), 2018: 87% (75–100)
- TB patients facing catastrophic total costs, 2018: 6% (5–7)
- TB/HIV care in new and relapse TB patients, 2018:
  - Number (%): 252
  - Patients with known HIV status who are HIV-positive:
    - on antiretroviral therapy: 3 1%
- Total cases notified: 252

Drug-resistant TB care, 2018
- % of bacteriologically confirmed TB cases tested for rifampicin resistance**: 100%
  - New cases: 100%
  - Previously treated cases: 100%
- Laboratory-confirmed cases*:
  - MDR/RR-TB: 0
  - XDR-TB: 0
- Patients started on treatment* **:
  - MDR/RR-TB: 0
  - XDR-TB: 0

Treatment success rate and cohort size
- New and relapse cases registered in 2017: 75% 238
- Previously treated cases, excluding relapse, registered in 2017: 0
- HIV-positive TB cases registered in 2017: 50% 2
- MDR/RR-TB cases started on second-line treatment in 2016: 0
- XDR-TB cases started on second-line treatment in 2016: 0
- Treatment success rate (%): 100

TB preventive treatment, 2018
- % of HIV-positive people (newly enrolled in care) on preventive treatment: 0%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 0% (0–0)

TB financing, 2019
- National TB budget (US$ millions): 0

*Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Generated: 2019-10-18